Vitamin C is an essential component of life that is prevalent in many foods (especially fruits) and produced by an abundance of chemical companies. This article focuses the chemical side of Vitamin C.
Whilst it is known by many scientists, it is virtually unknown by the public that Vitamin C has two totally and distinctly different separate sides (as indeed many chemicals do). The two sides of vitamin C consist of L-ascorbic acid which is the (-) side and D-Ascorbic acid which is the (+) side. It is the L-ascorbic acid that is the active side and the side that is beneficial to mankind.
Most research shows that the D-side of Ascorbic acid is discarded by the body and designated as little or no-use. People ingesting vitamin C are therefore only likely to benefit from the L side of vitamin C.
Vitamin C is not a stable substance and both the L and D sides are subject to change if moisture or water is added. For example, in an orange the Vitamin C is primarily the L-side and remains so in the surroundings of the orange whilst on the tree. However, when the juice is extracted from the orange after a period of days the L side changes to D and the juice will eventually even out at 50% D and 50% L content.
Frozen concentrated orange juice when thawed and water added will produce the exact same reaction. This also takes place when manufacturers add vitamin C to juices or drinks.
The assumption the public is under is that vitamin C added as a supplement during the manufacture of any liquid is all beneficial; this is a myth. The facts are that adding vitamin C to drinks may constitute only 50-60% L, with the remainder being the D side. Although it is believed that the body discards the D side of vitamin C, further research needs to be undertaken to confirm this theory. It may be that is some individuals that an abundance of the D side of vitamin C could conceivably be detrimental to their optimal health.
A number of companies produce vitamin C with varying degrees of purity of L-ascorbic acid. Discovery Experimental’s research produced only one manufacturer who was producing a consistent 99.9% purity level. Additionally, most of tablet manufacturers add ingredients to the L-ascorbic acid. The most prevalent being rose-hips, along with fillers such as starch, sucrose, talc, povidone and a battery of other substances that help bind the pills together.
The average ‘make-up’ of a pill being manufactured today is about 25% filler. Some of these fillers can be compromised in some part by chemicals that are not normally ingested into the human body as food. It’s possible that in some cases that pill fillers are detrimental to overall health in some individuals, and indeed can be the cause of side effects.
As many people take vitamin C in dosages of 1000mg per day, they would be ingesting 250mg of pill fillers, or if taking 10,000mg per day be ingested 2500mg of pill fillers on average. Pill filler can even cause the Ascorbic acid to break down and ‘go off.’
STABILITY OF VITAMIN C
Discount houses and some firms (and indeed some pharmacies) sell vitamin C under all kinds of names at competitive prices. The producers range from people in their garage to multi-national concerns. Discovery Experimental purchased at random 1g vitamin C tablets from three different companies, also vitamin C powder from two different mail-order houses. All five varieties of vitamin C proved ‘unstable’ and ‘went-off’ in a relatively short period of time, as such their effectiveness decreased enormously.
The worst example was a vitamin C purchased from a large nation-wide discount chain located in the western part of the United States. The vitamin C had no preservatives and was made up of about 25% fillers. The product was made in January 1991 but by June of 1991 the product was becoming unstable. By December of 1991 the product should not have been ingested and by December of 1992 anyone even looking at the product would have thrown it out. However, stamped on the label was an expiry date of July 1995!
L-ascorbic acid at 99.9% purity is, in itself, an extremely stable substance subject only to high moisture. In testing at 99.9% purity, under normal conditions at room temperature, an unsealed bottle being opened twice daily for 2 to 21/2 years proved to be extremely stable.
PURITY INCREASES EFFECTIVENESS
In most cases and with very few exceptions, the purer the active ingredient is in products, (whether it is a pharmaceutical or a vitamin), the more potent and stable the product remains, and thus the more effective a product is.
Many producers of vitamin C are cutting quality in order to produce a cheaper, less pure product in order to remain competitive. Not only are doctors and the public unaware of the two sides of vitamin C and the reduced effectiveness of vitamin C when added to juices, but there is also the question mark over the purity of their particular brand of vitamin C (most regulatory bodies such as the FDA do not require purity levels to be stated on labels).
The public (and probably many doctors) do not realize that it takes considerably less L-ascorbic acid at 99.9% purity to produce the same effects as a good deal more of the less pure, less stable forms of vitamin C offered on the market today.
DISPENSING, ADMINISTRATION & INDICATIONS
Research indicates that for maximum effectiveness vitamin C should not be pilled. It should be dispensed by the producer at a humidity level not exceeding 40% either as capsules or powder. To be most effective, the 99.9% L-ascorbic acid should be taken once or twice daily from 200mg to 3000mg, mixed or taken with condensed orange juice made with distilled water. People allergic to orange juice should mix the product with distilled water only. This way according to the research findings the effectiveness of vitamin C is maximised.
A NOBEL L’AUREATE’S FINDINGS
Everyone agrees that the famous Nobel Laureate Linus Pauling was the expert on vitamin C and the Linus Pauling Institute has amassed the greatest single amount of data about vitamin C.
As a result there is a great deal of information available, for example we know that the human body cannot store Vitamin C and unlike other mammals we can’t manufacture our own supplies. Thus vitamin C is a vital daily component of our diets.
There are many benefits of optimal vitamin C supplementation, clinical research indicates that L-ascorbic acid administered in varying amounts to be effective in reducing the risks of cancer at an average of 20% in males and 14% in women.
Vitamin C has been shown to reduce the risks of heart disease on average by 40% in men and 20% in women.
Furthermore vitamin C is effective in depression, bruising, pallor, cataracts, common colds, flu, infections, lethargy, strength, healing of wounds, chelation and nominal life extension.
INDICATIONS FOR CHELATION
Private trials conducted by physicians and scientists using 99.9% purity L-ascorbic acid with distilled water and concentrated orange juice have reported some remarkable preliminary findings regarding chelation (the removal of toxic metals from the body).
Dosages of 3,000mg daily are indicating the removal of aluminium from brain cells. This discovery could lead to a direct relationship and benefit for Alzheimer’s disease and other neurological disorders. Also reported were people scheduled for by-pass surgery (due to the blockage of their arterial walls) being treated with body tolerant levels of 99.9% purity L-ascorbic acid and 30mg of Aspirin daily for 8 weeks. The need for by-pass surgery was dissipated for some patients as their arterial wall blockage was dramatically reduced! These results substantiate earlier findings namely that regular vitamin C use reduces the risk of heart disease.
There is no doubt that vitamin C is a vital and highly credible supplement. Millions of individuals are taking vitamin C on a daily basis, some to help their problem many more as an act of faith to prevent disease and disorder.
However, in order to maximise the benefit of vitamin C supplementation it is advisable to discover if your vitamin C manufacturer produces the L-ascorbic acid at the 99.9% purity, as this most assuredly makes a substantial difference in its effectiveness. Additionally, vitamin C in pill form should be avoided.
You will be pleased to learn that IAS is now stocking the Discovery Experimental Vitamin C, which is L-ascorbic acid at 99.9% purity.
LiCC: Change of Creatine Phosphokinase and Malondialdehyde in the Serum and Clinical Use of Large Doses of Vitamin C Following Open Heart Surgery. Chinese Journal of Surgery, 1990 January, 28(1): 16-7, 60-1.
2) Nishinaka Y, et al: The Effects of a High Dose of Ascorbate on Ischemia-Reperfusion Induced Mitochondrial Dysfunction in Canine Hearts. Hearts and Vessels, 1992, 7(1): 18-23.
3) Hori M, et al: Role of Oxygen-Derived Free Radicals in Myocardial Edema and Ischemia in Coronary Microvascular Embolization. Circulation, 1991 August, 84(2): 828-40.
4) Poliukhovich GS, et al: Efficacy of Various Antioxidants in Experimental Ischemia and Myocardial Infarct in the Rat. Voprosy Meditsinskoi Khimii, 1991 July-August, 37(4): 54-6.
5) Cameron E, et al: Innovation vs Quality Control: An ‘unpublishable’ Clinical Trial of Supplemental Ascorbate in Incurable Cancer. Medical Hypotheses, 1991 November, 36(3): 185-9.
6) Trout DL: Vitamin C and Cardiovascular Risk Factors. American Journal of Clinical Nutrition, 1991 January, Vol 53, Supplement 1, 322S-325S.
7) Tada II, et al: Effects of Pretreatment with 2-0-Octadecylascorbic Acid, A Novel Free Radical Scavenger, on Reprefusion_Induced Arrhythmias in Isolated Perfused Rat Hearts. Journal of Cardiovascular Pharmacology, 1990 December, 16(6):984-91.
8) Pietri S, et al: Ascorbyl Free Radical as a Reliable Indicator of Free Radical-Mediated Myocardial Ischemic and Post-Ischemic Injury. European Journal of Biochemistry, 1990 November 13, 193(3): 845-54.
9) Ricmersma RA, et al: Plasma Antioxidants and Coronary Heart Disease: Vitamin C and E, and Selenium. European Journal of Clinical Nutrition, 1990 February, 44(2): 143-50.
10) Arduini A, et al: Detection of Ferryl Myoglobin in the Isolated Ischemic Rat Heart. Free Radical Biology and Medicine, 1990, 9(6): 511-3.
11) Parvianinen MT, Salonen JT: Vitamin C Status of 54-year old Eastern Finnish Men Throughout the Year. International Journal for Vitamin and Nutrition research, 1990, 60(1). 47-51.
12) Tanabe M, Kito G: Effects of CV-3611, A New Free Radical Scavenger, On Ischemic Heart Failure in Conscious Beagle Dogs. Japanese Journal of Pharmacology, 1989 August, 50(4): 467-76.
13) Filev LV, et al: The Methemoglobin Content in Intact Erythrocytes and its Alteration Under the Influence of Chromosmon, Ascorbic Acid, Riboflavin and Glutathione. Tsitologiia, 1989 March, 31(3): 336-43.
14) Barsaachi R, et al: Increased Ultra Weak Chemiluminescence Emission from Rat Heart at Postischemic Reoygenation: Protective Role of Vitamin E. Free Radical Biology and Medicine, 1989, 6(6): 573-9.
15) Salonen JT, et al: Blood Pressure, Dietary Fats, and Antioxidants. American Journal of Clinical Nutrition, 1988 November, 48(5):1226-32.
16) Salonen JT, et al: Relationship of Serum Selenium and Antioxidants to Plasma Lipoproteins, Platelet Aggregability and Prevalent Ischemic Heart Disease in Eastern Finnish Men. Atherosclerosis, 1988 March, 70(1-2): 155-60.
17) Enstrom JE, et al: Vitamin C Intake and Mortality Among a Sample of the United States Population. Epidemiology, 1992 May, 3(3): 194-202.
18) Simon JA: Vitamin C and Cardiovascular Disease. Journal of the American College of Nutrition, 1992 April, 11(2): 107-25.
19) Barta E, et al: Protective Effect of Alpha-Tocopherol and L-ascorbic Acid Against the Ischemic-Reperfusion Injury in Patients during Open-Heart Surgery. Bratislavske Lekarske Listy. 1991 March-April, 92(3-4): 174-83.
20) Nathan N, et al: Role of Vitamin C on Adrenocortical Effects of Etomidate. Annales Francaises D Anesthesie et de Reanimation, 1991, 10(4): 329-32.
21) Singh RB, et al: Dietary Strategies for Risk-Factor Modification to Prevent Cardiovascular Diseases. Nutrition, 1991 May-June, 7(3): 210-4.
22) Rath M, Pauling L: Hypothesis: Lipoprotein(a) is a Surrogate for Ascorbate. Proceedings of the National Academy of Sciences of the United States of America, 1990 August, 87(16): 6204-7.
23) Mickle DA, et al: Myocardial Salvage with Trolox and Ascorbic Acid for an Acute Evolving Infarction. Analysis of Thoracic Surgery, 1989 April, 47(4): 553-7.
24) Riemersma RA, et al: Low Plasma Vitamins E and C, Increased Risk of Angina in Scottish Men. Annals of the New York Academy of Science, 1989, 570:291-5.
25) Vidgren M, et al: Absorption of Ascorbic Acid from a Film-Coated Tablet and from a New Enteric-Coated Pellet. Preparation in Subjects with Inadequate Plasma Levels of Ascorbic Acid. Arzneimittel-Forschung, 1992 February, 42(2):143-6.
26) Mostafa S, et al: Beneficial Effects of Vitamin C on Risk Factors of Cardiovascular Diseases. Journal of the Egyptian Public Health Association. 1989, 64(1-2):123-33.
27) Paganelli GM, et al: Effect of Vitamin A, C and E supplementation on Rectal Cell Proliferation in Patients with Colorectal Adenomas. Journal of the National Cancer Institute, 1992 January 1, 84(1):47-51.
28) Maderazo EG, et al: A Randomized Trial of Replacement Antioxidant Vitamin Therapy for Neutrophil Locomotory Dysfunction in Blunt Trauma. Journal of trauma, 1991 August, 31(8): 1142-50.
29) Yillar DO, et al: Multivitamin Supplementation in Oral Contraceptive Users. Contraception, 1991 September, 44(3):277-88.
31) Penn ND, et al: The Effect of Dietary Supplementation with Vitamins A, C and E on Cell-Mediated Immune Function in Elderly Long-Stay Patients. Age and Ageing, 1991 May, 20(3): 169-74.
32) Salonen JT, et al: Effects of Antioxidant Supplementation on Platelet Function. American Journal of Clinical Nutrition, 1991 May, 53(5):1222-9.
33) Filina AA, Sporova NA: Effect of Lipoic Acid on Tryosine Metabolism in Patients with Open-Angle Glaucoma. Vestnik Oftalmologii, 1991 May-June, 107(3):19-21.
34) Triana Mantilla ME, et al: The Effect of vitamin C on the Lipolytic Activity in Type-II Diabetics with Angiopathy. Angiologia, 1991 March-April, 43(2): 77-81.
35) Riemersma RA, et al: Risk of Angina Pectoris and plasma Concentrations of Vitamins A, C, and E and Carotene. Lancet, 1991 January 5, 337(8732):1-5.
36) Podoshin L, et al: Treatment of Perennial Allergic Rhinitis with Ascorbic Acid Solution. Ear, Nose, and Throat Journal, 1991 January, 70(1):54-5.
37) Birwe H, et al: Investigations of the Efficacy of Ascorbic Acid Therapy in Cystinuria. Urological Research, 1991, 19(3): 199-201.
38) Bucca C, et al: Effects of Vitamin C on Histamine Bronchial Responsiveness of Patients with Allergic Rhinitis. Annals of Allergy, 1990 October, 65(4):311-4.
39) Johnston CS: Effect of a Single Oral Dose of Ascorbic Acid on Body Temperature and Trace Mineral Fluxes in Healthy Men and Women. Journal of the American College of Nutrition, 1990 April, 9(2): 150-4.
40) Bjornstrom M, et al: Comparison Between Saliva Substitutes in Patients with Symptoms Related to Dry Mouth. Swedish Dental Journal, 1990, 14(4): 153-61.
41) Boidin Mp, et al: Ascorbic Acid Prevents Cimetidine-Induced Decreases of Serum Hydrocortisone Concentrations. Pharmaceutisch Weekblad, Scientific Edition, 1990 August 24, 12(4): 151-3.
42) Hill J, Bird HA: Failure of Selenium-Ace to Improve Osteoarthritis. British Journal of Rheumatology, 1990 June, 29(3):211-3.
43) DeCosse JJ, et al: Effect of Wheat Fiber and Vitamins C and E on Rectal Polyps in Patients with Familial Adenomatous Polyposis. Journal of the National Cancer Institute, 1989 September 6, 81(17):1290-7.
44) Berenson M, et al: Reported Compliance in a Chemoprevention Trial for a Familial Adenomatous Polyposis. Journal of Behavioral Medicine, 1989 June, 12(3):233-47.
45) McKeown-Eyssen G, et al: A Randomized Trial of Vitamins C and E in the Prevention of Recurrence of Colorectal Polyps, Cancer Research, 1988 August 15, 48(16):4701-5.
46) Bagnis R, et al: Evaluation of the Efficacy of Mannitol in the Treatment of Ciguatera in French Polynesia. Medicine Tropicale, 1992 January-March, 52(1):67-73.
47) Howe GR, et al: A Collaborative Case-Control Study of Nutrient Intake and Pancreatic Cancer within the Search Programme. International Journal of Cancer, 1992 May 28, 51(3): 365-72.
48) Moore GL, et al: Ascorbate-2-Phosphate in Red Cell Preservation. Transfusion, 1988 May-June, 28(3):221-5.
49) Aro A, et al: No Effect on Serum Lipids by Moderate and High Doses of Vitamin C in Elderly Subjects with Low Plasma Ascorbic Acid Levels. Annals of Nutrition and Metabolism, 1988, 32(3): 133-7.
50) Block G: Epidemiologic Evidence regarding Vitamin C and Cancer. American Journal of Clinical Nutrition, 1991 December, Vol 54, Supplement 6, 1310S-1314S.
51) Weis JR, et al: Oxidized Low-Density Lipoprotein Increases Cultured Human Endothelial Cell Tissue Factor Activity and Reduces Protein C Activation. Faseb Journal, 1991 July, 5 (10): 2459-65.
52) Karpel R, et al: Free Radical-Induced Fibrinogen Coagulation: Modulation of Neofibe Formation by Concentration, pH and Temperature. Israel Journal of Medical Sciences, 1991 February, 27(2): 61-6.
53) Negre-Salvayre A, et al: Additional Antilipoperoxidant Activities of Alpha-Tocopherol and Ascorbic Acid on Membrane-like Systems are Potentiated by Rutin. Pharmacology, 1991, 42(5):262-72.
54) Radh II: Cellular Functions of Ascorbic Acid. Biochemistry and Cell Biology, 1990 October, 68(10): 1166-73.
55) Niki E: Action of Ascorbic Acid as a Scavenger of Active and Stable Oxygen Radicals. American Journal of Clinical Nutrition, 1991 December, Vol. 54, Supplement 6, 1119S-1124S.
56)Sevanian A, et al: Serum Urate as an Antioxidant for Ascorbic Acid. American Journal of Clinical Nutrition, 1991 December, Vol. 54, Supplement 6, 1129S-1134S.
57) Moller ME, et al: A Possible Role of the Dietary Fibre Product, Wheat Bran, as a Nitrite Scavenger. Food and Chemical Toxicology, 1988 October, 26(10): 841-5.
58) Mogelvang B: Can Arteriosclerosis be Prevented by Antioxidants? Nordisk Medicin, 1992, 107(2):53-6.
59) Frei B: Ascorbic Acid Protects Lipids in Human Plasma and Low-Density Lipoprotein Against Oxidative Damage. American Journal of Clinical Nutrition, 1991 December, Vol. 54, Supplement 6, 1113S-1118S.
60) Gutteridge JM: Plasma Ascorbate Levels and inhibition of the Antioxidant Activity of Caeruloplasmin. Clinical Science, 1991 September, 81(3):413-7.
61) Frei B, et al: Ascorbate: The Most effective Antioxidant in Human Blood plasma. Advances in Experimental Medicine and Biology, 1990, 264:155-63.
62) Frei B, et al: Ascorbate is an Outstanding Antioxidant in Human Blood Plasma. Proceedings of the National Academy of Sciences of the United States of America, 1989 August, 86(16):6377-81.
63) Bachowski GJ, et al: Ascorbate-Enhanced Lipid Peroxidation in Photooxidized Cell Membranes. Lipids, 1988 June, 23(6):580-6.
64) Frankel EN: The Antioxidant and nutritional Effects of Tocopherols, Ascorbic Acid and beta-Carotene in Relation to Processing of edible Oils. Bibiotheca Nutritio et Dieta, 1989, (43):297-312.
65) Dorgan JF, Schatzkin A: Antioxidant Micronutrients in Cancer Prevention. Hematology Oncology Clinics of North America, 1991 February, 5(1):43-68.
66) Block G: Vitamin C and Cancer Prevention: The Epidemilologic Evidence. American Journal Of Clinical Nutrition, 1991 January, Vol. 53, Supplement 1, 270S-282S.
67) Singh VN, Gaby SK: Premalignant Lesions: Role of Antioxidant Vitamins and Beta-Carotene in Risk Reduction and prevention of Malignant Transformation. American Journal of Clinical Nutrition, 1991 January, Vol. 53, Supplement 1, 386S-390S.
68) Costa A, et al: Cancer Chemoprevention. A Review of Ongoing Clinical Studies. Acta Oncologica, 1990, 29(5): 657-63,
69) Chen LH, et al: Vitamin C, Vitamin E and Cancer. Anticancer Research, 1988 July-August, 5(4): 739-48.
70) Juliano L, et al: Mechanism of Reaction of a Suggested Superoxide-Dismutase Mimic, FE(II)-N,N,NÕ,NÕ-tetrakis (2-pyridylmethyl) Ethylenediamine. Archives of Biochemistry and Biophysics, 1992 February 14, 293(1):153-7.
71) Geesin JC, et al: Regulation of Collagen Synthesis by Ascorbic acid: Characterization of the Role of Ascorbate-Stimulated Lipid Peroxidation. Archives of Biochemistry and Biophysics, 1991 October, 290(1):127-32.
72) Gomex M, et al: Effectiveness of Some Chelating Agents on Distribution and Excretion of Vanadium in Rats after Prolonged Oral Administration. Journal of Applied Toxicology, 1991 June, 11(3): 195-98.
73) Lund LG, Aust AE: Mobilization of iron From Crocidolite Asbestos by Certain Chelators Results in Enhanced Crocidolite-Dependent Oxygen Consumption. Archives of Biochemistry and Biophysics, 1991 May 15, 287(1): 91-6.
74) Woodhead JC, et al: Gender-Related Differences in Iron Absorption by Preadolescent Children. Pediatric Research, 1991 May, 29(5): 435-9.
75) Laulhere JP, et al: Photoreduction and Incorporation of Iron into Ferritins, Biochemical Journal, 1990 July 1, 269(1): 79-84.
76) Shinar E, et al: Oxidative Damage to Human Red Cells Induced by Copper and Iron Complexes in the Presence of Ascorbate. Biochemica et Biophysica Acta, 1989 October 30, 1014(1):66-72.
77) Rice-Evans C, et al: The Interactions of Desferrioxamine and Hydroxypyridone Compounds with Haemoglobin and Erythrocytes. Febs Letters, 1989 October 9, 256(1-2):17-20.
78) Beyer WF Jr, Fridovich I: Characterization of a Superoxide Dismutase Mimic Prepared from Desferrioxamine and Mn02. Archives of Biochemistry and Biophysics, 1989 May 15, 271(1): 149-56.
79) Abe A, et al: Sensitive, Direct Colorimetric Assay for Copper in Serum. Clinical Chemistry, 1989 April, 35(4):552-4.
80) Monteiro HP, et al: An Iron Chelator is not Required for Reductive Iron Release from Ferritin by Radical Generating Systems. Free Radical Research Communications, 1989, 7(1):33-5.
81) Gomez M, et al: Effectiveness of Chelation Therapy with Time after Acute Vanadium Intoxication. Journal of Applied Toxicology, 1988 December, 8(6):439-44.
82) Wilgus H, Roskoski R Jr: Inactivation of Tyrosine Hydroxylase Activity by Ascorbate in vitro and in Rat PC12 Cells. Journal of Neurochemistry, 1988 October, 51(4):1232-9.
83) Pileblad E, et al: Studies on the Autoxidation of Dopamine: Interaction with Ascorbate. Archives of Biochemistry and Biophysics, 1988 June, 263(2):447-52.
84) Dahwan M, et al: Influence of Thiamine and Ascorbic Acid Supplementation on the Antidotal Efficacy of Thiol Chelators in Experimental Lead Intoxication. Archives of Toxicology, 1988, 62(4):301-4.